VolitionRx Limited VNRX
Set alert
As of Nov 2, 2:37 PM ET
- YTD
- -95.91%
- 1 year
- -97.53%
- Open
- 0.2001
- Prev close
- 0.1953
- Mkt cap
- 6.37M
- Vol
- 1.06M
- Avg vol
- 8.70M
- EPS
- -3.80
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.195
- High
- 0.22
- Forward P/E
- -3.83
- Beta
- 1.10
- Short ratio
- 3.71
- Inst. own
- 19.11%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.6652
- 200-d avg
- 0.6969
- 1y target
- 3.34
5D chart
Signals (85)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Nov 2, 11:00 AM | 3 hours ago |
| SMA: Bearish | Nov 2, 10:55 AM | 3 hours ago |
| RSI: Overbought | Nov 2, 10:35 AM | 4 hours ago |
| RSI: Overbought | Nov 2, 10:05 AM | 4 hours ago |
| SMA: Bullish | Oct 30, 3:50 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:45 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:55 PM | 3 days ago |
| SMA: Bearish | Oct 30, 2:50 PM | 3 days ago |
| SMA: Bullish | Oct 30, 2:00 PM | 3 days ago |
| SMA: Bullish | Oct 30, 1:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 1:55 PM | 3 days ago |
| SMA: Bearish | Oct 30, 1:25 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 1:25 PM | 3 days ago |
| SMA: Bullish | Oct 30, 1:20 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 1:20 PM | 3 days ago |
| SMA: Bearish | Oct 30, 12:20 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 12:20 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 12:00 PM | 3 days ago |
| SMA: Bullish | Oct 30, 11:55 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:45 AM | 3 days ago |
| SMA: Bullish | Oct 30, 11:40 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 11:25 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 11:20 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 11:10 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:05 AM | 3 days ago |
| SMA: Bullish | Oct 30, 11:00 AM | 3 days ago |
| SMA: Bearish | Oct 30, 10:55 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 10:50 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:15 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:40 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 9:40 AM | 3 days ago |
| RSI: Overbought | Oct 29, 3:35 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 3:30 PM | 4 days ago |
| SMA: Bullish | Oct 29, 3:25 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 1:45 PM | 4 days ago |
| SMA: Bearish | Oct 29, 1:35 PM | 4 days ago |
| RSI: Overbought | Oct 29, 1:10 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 12:55 PM | 4 days ago |
| SMA: Bullish | Oct 29, 12:50 PM | 4 days ago |
| SMA: Bearish | Oct 29, 12:45 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 12:45 PM | 4 days ago |
| SMA: Bullish | Oct 29, 12:35 PM | 4 days ago |
| SMA: Bearish | Oct 29, 12:25 PM | 4 days ago |
| RSI: Overbought | Oct 29, 12:10 PM | 4 days ago |
| RSI: Overbought | Oct 29, 12:00 PM | 4 days ago |
| SMA: Bullish | Oct 29, 11:40 AM | 4 days ago |
| SMA: Bearish | Oct 29, 11:35 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 29, 10:25 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:20 AM | 4 days ago |
| SMA: Bearish | Oct 29, 9:50 AM | 4 days ago |
| SMA: Bearish | Oct 29, 9:50 AM | 4 days ago |
| SMA: Bullish | Oct 29, 9:45 AM | 4 days ago |
| SMA: Bullish | Oct 29, 9:45 AM | 4 days ago |
| SMA: Bearish | Oct 29, 9:30 AM | 4 days ago |
| RSI: Oversold | Oct 29, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 3:45 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 5 days ago |
| SMA: Bearish | Oct 28, 3:15 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 3:10 PM | 5 days ago |
| RSI: Overbought | Oct 28, 2:40 PM | 5 days ago |
| RSI: Overbought | Oct 28, 2:15 PM | 5 days ago |
| RSI: Overbought | Oct 28, 2:00 PM | 5 days ago |
| SMA: Bullish | Oct 28, 1:10 PM | 5 days ago |
| SMA: Bullish | Oct 28, 1:10 PM | 5 days ago |
| SMA: Bearish | Oct 28, 12:40 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 11:25 AM | 5 days ago |
| RSI: Oversold | Oct 28, 10:10 AM | 5 days ago |
| RSI: Oversold | Oct 28, 9:55 AM | 5 days ago |
| RSI: Oversold | Oct 28, 9:40 AM | 5 days ago |
| SMA: Bearish | Oct 27, 3:45 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:10 PM | 6 days ago |
| MACD: Sell Signal | Oct 27, 3:10 PM | 6 days ago |
| SMA: Bullish | Oct 27, 2:20 PM | 6 days ago |
| SMA: Bearish | Oct 27, 2:15 PM | 6 days ago |
| RSI: Overbought | Oct 27, 1:50 PM | 6 days ago |
| MACD: Buy Signal | Oct 27, 1:45 PM | 6 days ago |
| SMA: Bullish | Oct 27, 1:15 PM | 6 days ago |
| SMA: Bearish | Oct 27, 1:10 PM | 6 days ago |
| SMA: Bullish | Oct 27, 1:05 PM | 6 days ago |
| SMA: Bearish | Oct 27, 12:30 PM | 6 days ago |
| SMA: Bullish | Oct 27, 12:20 PM | 6 days ago |
| SMA: Bullish | Oct 27, 12:05 PM | 6 days ago |
| SMA: Bearish | Oct 27, 12:00 PM | 6 days ago |
| SMA: Bearish | Oct 27, 11:30 AM | 6 days ago |
News
-
6 days ago benzinga.com
VolitionRx Executes Non-Binding Letter Of Intent With Missionpharma A/S To Develop, Roll Out Volition's Prototype Lateral Flow Technology For NETosis
VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has executed a non-binding Letter of Intent ("LOI") with Missionpharma A/S, a Danish global
6 days ago prnewswire.com
VolitionRx Signs LOI with Missionpharma to explore the Development and Launch of Volition's Lateral Flow Technology for NETosis Worldwide
HENDERSON, Nev., Oct. 27, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has executed a non-binding Letter…
-
6 days ago benzinga.com
VolitionRx Makes $500K Cash Partial Prepayment Towards Outstanding Principal Balance On Its Senior Secured Convertible Promissory Note
Note dated January 15, 2026, in the original principal amount of $2,400,000 (the "Note"), issued to Lind Global Asset Management XII LLC ("Lind"). Following the partial pre-payment, the remaining
6 days ago prnewswire.com
VolitionRx Limited Announces $500,000 Partial Pre-Payment of Convertible Note in Cash
Reduces outstanding principal to only $0.7 million on the $2.4 million note and brings total debt reduction across both notes to over $5.0 million since June 30, 2026. Secures agreement pausing…
2 weeks ago defenseworld.net
VolitionRX (NYSEAMERICAN:VNRX) Stock Breaks Below 50 Day Moving Average – What’s Next?
VolitionRX Limited (NYSEAMERICAN:VNRX - Get Free Report) crossed below its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $0.35 and traded as low as $0.1801.…
1 month ago prnewswire.com
VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France
HENDERSON, Nev., Sept. 17, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ( XASE: VNRX ) (together with affiliates "Volition"), a multi-national epigenetics company, as part of the…
-
1 month ago benzinga.com
VolitionRx Launches DETECSEPS Sepsis Detection Project With ~$7.3M French Government Funding
French Government-Funded €6.3 million (~$7.3 million) Consortium Selects Volition's Nu.Q® NETs Assay as Sole Biomarker for France's Real World Evaluation of Early Detection of SepsisHENDERSON, Nev.,…
1 month ago prnewswire.com
VolitionRx Participates in Launch of DETECSEPS Program in France
French Government-Funded €6.3 million (~$7.3 million) Consortium Selects Volition's Nu.Q® NETs Assay as Sole Biomarker for France's Real World Evaluation of Early Detection of Sepsis HENDERSON, Nev.,…
-
1 month ago benzinga.com
VolitionRx Fully Pays Off $7.5M Convertible Promissory Note, Dated May 20, 2025
VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces the full pre-payment in cash of the outstanding balance on its senior secured convertible promissory…
1 month ago prnewswire.com
VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027
Reduces Equity Overhang HENDERSON, Nev., Sept. 14, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the full…
1 month ago prnewswire.com
Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference
Targets $36 Billion TAM in Early Cancer Detection and MRD. HENDERSON, Nev.
1 month ago defenseworld.net
VolitionRX (NYSEAMERICAN:VNRX) Share Price Crosses Below Fifty Day Moving Average – Here’s Why
Shares of VolitionRX Limited (NYSEAMERICAN:VNRX - Get Free Report) crossed below its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $0.87 and traded as low…
2 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Redhill Biopharma (NASDAQ:RDHL) shares increased by 96.7% to $1.3 during Monday's pre-market session. The market value of their outstanding shares is at $4.0 million. Vivos Therapeutics…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Aardvark Therapeutics (NASDAQ:AARD) shares increased by 8.5% to $6.28 during Friday's after-market session. The market value of their outstanding shares is at $144.8 million. TransCode…
2 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 41.4% to $7.29 during Friday's pre-market session. The company's market cap stands at $10.3 million. Aethlon Medical (NASDAQ:AEMD) stock moved…
2 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Celularity (NASDAQ:CELU) stock moved upwards by 134.0% to $2.06 during Thursday's regular session. The company's market cap stands at $25.0 million. Propanc Biopharma (NASDAQ:PPCB) stock…
2 months ago benzinga.com
Nasdaq Surges 200 Points; Nvidia Posts Upbeat Q2 Results
US stocks traded higher with Nasdaq up 200 points. Dow down 0.01%, Nasdaq up 0.77%, and S&P 500 up 0.27%. Tech shares rose 2.2% while consumer staples fell 1.1%. Nvidia reported strong earnings.…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers VolitionRX (AMEX:VNRX) shares increased by 102.2% to $0.69 during Thursday's pre-market session. The company's market cap stands at $4.8 million. NewcelX (NASDAQ:NCEL) shares increased by…
2 months ago benzinga.com
Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations
VolitionRx Limited (NYSE:VNRX) stock is surging on Thursday after the diagnostics company reported a 112% year-over-year revenue surge in the first half of 2026, reaching $1.4 million as it expanded…
2 months ago benzinga.com
Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations
VolitionRx reports 112% revenue growth in H1 2026 while advancing its Nu.Q diagnostic platforms across sepsis and oncology markets.
2 months ago benzinga.com
Why Salesforce Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
Salesforce Inc (NYSE: CRM) stock rose on good Q2 results and raised FY27 guidance, while other tech stocks saw gains in early trading.Salesforce (NYSE: CRM) jumps on strong Q2 results and raised…
-
2 months ago benzinga.com
VolitionRx Reports 112% H1 Revenue Growth, Advances Toward $5M Veterinary Milestone
112% H1 Revenue Growth, Advance Toward $5 Million Veterinary Milestone, Newly Announced Collaboration and Active Licensing Discussions with More Than a Dozen Global Diagnostic LeadersHENDERSON, Nev.,…
2 months ago prnewswire.com
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
112% H1 Revenue Growth, Advance Toward $5 Million Veterinary Milestone, Newly Announced Collaboration and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders HENDERSON,…
-
2 months ago benzinga.com
VolitionRx Announces Publication Of Peer-Reviewed Paper And Editorial Indicating That Its Nu.Q NETs H3.1 Biomarker Is An Independent Predictor Of 28-Day Mortality And Need For Renal Replacement Therapy In Sepsis And Septic Shock Patients
Entitled "H3.1 Nucleosomes to Predict Renal Replacement Therapy and Mortality in Sepsis—A Secondary Analysis of the SISPCT Randomized Control Trial1" and published in Critical Care Medicine, the…
2 months ago prnewswire.com
Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis
Published in Critical Care Medicine , findings confirm high-predictive accuracy for severe sepsis outcomes, driving commercial momentum across Volition's $2.8 billion addressable market. HENDERSON,…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Nuwellis (NASDAQ:NUWE) stock increased by 27.2% to $1.22 during Wednesday's pre-market session. The market value of their outstanding shares is at $3.0 million. Summit Therapeutics…
2 months ago seekingalpha.com
VolitionRx Limited (VNRX) Q2 2026 Earnings Call Transcript
VolitionRx Limited (VNRX) Q2 2026 Earnings Call Transcript
2 months ago benzinga.com
VolitionRX Reports Q2 2026 Results: Full Earnings Call Transcript
On Friday, VolitionRX (AMEX:VNRX) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call…
-
2 months ago benzinga.com
VolitionRX Q2 EPS $(0.85) Misses $(0.57) Estimate, Sales $398.657K Miss $482.667K Estimate
VolitionRX (AMEX:VNRX) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.57) by 49.12 percent. This is a 1316.67 percent decrease over losses of…
2 months ago prnewswire.com
VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for Friday, August 14 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.
-
2 months ago benzinga.com
VolitionRx Announces That Results Utilizing Its Lateral Flow Prototype Are Highly Correlated With Results Utilizing Its Legacy Automated Nu.Q® NETs Test In Critically Ill Sepsis Patients
This new lateral flow finger prick sample test could be used to rapidly identify high-risk patients in the ER or at the bedside, thereby greatly expanding the potential market beyond centralized lab…
2 months ago prnewswire.com
Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients
Removes Centralized Lab Dependency for $3.8 Billion Global Addressable Market for NETosis Testing HENDERSON, Nev., Aug. 12, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"),…
2 months ago prnewswire.com
VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update
Conference call to take place on Friday, August 14 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.
2 months ago prnewswire.com
Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology
Targets $36 Billion TAM in Early Cancer Detection and MRD. Company in active discussions with global diagnostic leaders to accelerate commercialization.
3 months ago prnewswire.com
Volition Advances Nu.Q® NETs Platform Towards Commercialization
Consistent international data positions Nu.Q® H3.1 as a potential "game changer" in sepsis management within a $3.8 billion addressable market HENDERSON, Nev., July 30, 2026 /PRNewswire/ --…
-
3 months ago benzinga.com
VolitionRx Publishes Paper On The Prognostic Value Of Its Nu.Q Cancer Assay In Newly Diagnosed Lung Cancer Patients
The clinical paper entitled "Prognostic value of circulating H3K27Me3-nucleosomes in newly diagnosed lung cancer patients: Real-world evidence1" has been written in conjunction with researchers and…
3 months ago prnewswire.com
VolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer Test
HENDERSON, Nev., July 7, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the release of a new clinical study…
-
4 months ago benzinga.com
VolitionRx Partners With Sysmex To Streamline Volition's Nu.Q NETs H3.1 Assay
VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces a collaboration with Sysmex (TYO:6869), a leader in global in vitro diagnostics, to optimize Volition's…
4 months ago prnewswire.com
VolitionRx Announces Collaboration with Sysmex
HENDERSON, Nev., June 17, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces a collaboration with Sysmex (TYO: 6869), a leader…
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
4 months ago prnewswire.com
VolitionRx Announces Pricing of $4.6 Million Public Offering
$4.6 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the full exercise of warrants HENDERSON, Nev., June 7, 2026 /PRNewswire/ -- VolitionRx Limited…
-
5 months ago benzinga.com
U.S. State Dept Announces Nearly $38M In Additional Funding Toward The Department's Ongoing Ebola Response Efforts
https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/
-
5 months ago benzinga.com
Full Transcript: VolitionRX Q1 2026 Earnings Call
Full Transcript: VolitionRX Q1 2026 Earnings Call
-
5 months ago benzinga.com
VolitionRX Q1 EPS $(0.97) Misses $(0.75) Estimate, Sales $985.076K Beat $426.600K Estimate
VolitionRX (AMEX:VNRX) reported quarterly losses of $(0.97) per share which missed the analyst consensus estimate of $(0.75) by 29.33 percent. This is a 1516.67 percent decrease over losses of…
-
6 months ago benzinga.com
VolitionRx Submits Clinical Manuscript For Peer Review Over Its Nu.Q Vet Feline Prototype Assay To Trace Lymphoma In Cats
VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces submission for peer review a clinical manuscript1 reporting the high accuracy of its Nu.Q® Vet Feline…
-
6 months ago benzinga.com
VolitionRx Launches Online Store After 10 Years Of Research Into Cancer Testing Tools, Starts Selling Lab-Ready Nucleosome Products Online To Boost Research Use
VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the launch of its rNuQ webshop offering a range of reliable, ready to use recombinant nucleosomes that we…